Abrégé

The present invention discloses modified corn plants which have been edited in specific cytokine dehydrogenase genes. These corn plants have a short stature phenotype and have an increased lodging resistance.

Classes IPC  ?

• A01H 5/10 - Graines
• A01H 6/46 - Gramineae ou Poaceae, p. ex. ivraie, riz, blé ou maïs
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The present invention relates to novel tumor-associated antigens (TAAs) useful in cancer vaccines. The present invention also relates to vaccines including such immunogens and/or nucleic acid molecules encoding the same. The present invention further relates to methods of using the vaccines for inducing immune responses and preventing and/or treating subjects having cancer cells or tumors that express these antigens, such as e.g. lung cancer.

Classes IPC  ?

• A61K 39/0011 -

Abrégé

According to an embodiment a guiding assembly (100) is disclosed for a shock wave turbo reactor, the assembly comprising a set of sections, each section having respective cylindrically shaped bodies with a shared axis (107). The guiding assembly is configured to be housed by a shock wave turbo reactor by enclosing said guiding assembly with a reactor shell thereby forming an axially enclosed volume defined by the volume enclosed between two surfaces of revolution having their respective centres coinciding with the shared axis (107), the first surface of revolution being an outer surface of the combined cylindrically shaped bodies of the sections and the second surface formed by the reactor shell when housed by a shock wave turbo reactor, the volume further being enclosed between an inlet (101) at a first axial end of the guiding assembly and an outlet (102) at a second, distal, end of the guiding assembly. The set of sections successively comprises : - a first component comprising a set of blades (104) tangentially distributed along its respective cylindrically shaped body and - a second component (105) comprising a helical ridge, which is wrapped uninterruptedly around its respective cylindrically shaped body thereby defining a helical flow channel for guiding the process fluid along the axial direction when following the helical flow channel, the second component (105) is configured to rotate in a rotation direction around the shared axis (107).

Classes IPC  ?

• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
• B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
• B01J 19/20 - Réacteurs fixes avec éléments internes mobiles en forme d'hélice, p. ex. réacteurs à vis
• F24V 40/00 - Production ou utilisation de la chaleur produite par le frottement interne de fluides en mouvement ou du frottement entre des fluides et des corps en mouvement

Abrégé

The present invention relates to carriers comprising mRNA encoding a HORMAD1 polypeptide, in particular mRNA-based vaccines, more in particular dendritic cell (DC) based vaccines. The present invention further relates to methods for preparing an immunotherapy agent and/or the use of the vaccines for inducing immune responses and preventing and/or treating subjects having cancer cells or tumors that express HORMAD1.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 40/19 - Cellules dendritiques
• A61K 40/24 - Cellules présentatrices d’antigènes [APC]
• A61K 40/34 - Peptides antigéniques
• A61K 40/42 - Antigènes associés au cancer

Abrégé

The present disclosure relates to lipid nanoparticle (LNP) compositions including at least one ionizable cationic lipid and Polyinosinic:polycytidylic acid (poly(I:C)), and compositions and formulations incorporating such LNP compositions. The disclosure also provides methods of using these compositions to elicit an immune response, including for the prevention or treatment of infectious diseases.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/1271 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères
• A61K 9/51 - Nanocapsules
• A61K 39/12 - Antigènes viraux
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

BradyrhizobiumBradyrhizobium bacterium having enhanced characteristics, including but not limited to enhanced adaptation to the low and medium root zone temperature for example in North- West Europe.

Classes IPC  ?

• A01N 63/20 - BactériesSubstances produites par des bactéries ou obtenues à partir de celles-ci
• A01P 21/00 - Régulateurs de croissance des végétaux
• C12N 1/20 - BactériesLeurs milieux de culture

Abrégé

The present invention generally relates to the field of the formulation and curing of polymeric resins. In particular, the present invention relates to a curable composition comprising a polyamidoamine as defined herein and epoxy resins made from such curable composition. The present invention also relates to processes for preparing epoxy resins and uses thereof.

Classes IPC  ?

• C08G 59/54 - Aminoamides
• C09D 163/00 - Compositions de revêtement à base de résines époxyCompositions de revêtement à base de dérivés des résines époxy
• C09J 163/00 - Adhésifs à base de résines époxyAdhésifs à base de dérivés des résines époxy

Abrégé

A method of provisioning a service in a communication network is described, in which the service comprises at least one virtual network function and at least one virtual network path, which at least one virtual network function and at least one virtual network path are to be implemented in the communication network. The method including obtaining affinity constraints and/or anti-affinity constraints relating to mapping the at least one virtual network path onto the communication network, optionally obtaining affinity constraints and/or anti-affinity constraints relating to mapping the at least one virtual network function onto the communication network, and mapping the at least one virtual network function and at least one virtual network path onto the communication network subject to said constraints.

Classes IPC  ?

• G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p. ex. pour le traitement simultané de plusieurs programmes
• G06F 9/50 - Allocation de ressources, p. ex. de l'unité centrale de traitement [UCT]
• H04L 12/24 - Dispositions pour la maintenance ou la gestion
• H04L 12/46 - Interconnexion de réseaux
• H04L 12/713 - Prévention ou récupération du défaut de routage, p.ex. reroutage, redondance de route "virtual router redundancy protocol" [VRRP] ou "hot standby router protocol" [HSRP] par redondances de nœud, p.ex. VRRP
• H04L 12/725 - Sélection d’un chemin de qualité de service [QoS] adéquate
• H04L 12/911 - Contrôle d’admission au réseau et allocation de ressources, p.ex. allocation de bande passante ou renégociation en cours de communication
• H04L 29/08 - Procédure de commande de la transmission, p.ex. procédure de commande du niveau de la liaison
• H04L 41/12 - Découverte ou gestion des topologies de réseau
• H04L 41/40 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p. ex. des réseaux de commutation de paquets en utilisant la virtualisation des fonctions réseau ou ressources, p. ex. entités SDN ou NFV
• H04L 41/5054 - Déploiement automatique des services déclenchés par le gestionnaire de service, p. ex. la mise en œuvre du service par configuration automatique des composants réseau
• H04L 45/302 - Détermination de la route basée sur la qualité de service [QoS] demandée
• H04L 45/586 - Association de routeurs de routeurs virtuels
• H04L 47/70 - Contrôle d'admissionAllocation des ressources
• H04L 67/51 - Découverte ou gestion de ceux-ci, p. ex. protocole de localisation de service [SLP] ou services du Web
• H04L 41/0895 - Configuration de réseaux ou d’éléments virtualisés, p. ex. fonction réseau virtualisée ou des éléments du protocole OpenFlow
• H04L 41/0896 - Gestion de la bande passante ou de la capacité des réseaux, c.-à-d. augmentation ou diminution automatique des capacités

Abrégé

Catheter for delivery of therapeutic liquid formulation Provided is a catheter (100) having a proximal end (10) and a distal end (12) for distribution of a liquid outflow, the catheter (100) comprising. First (120) and second (140) lumens are comprised in a tube (160) wherein a lumen (162) of the tube is partitioned into the first (120) and second (140) lumens by a partitioning wall (150) attached to the tube lumen wall (164), the outlets (122a to c) of the plurality on the distal (12) side of the distribution inlet (110) are longitudinally positioned and sized in mirrored symmetry with the plurality of outlets (122d to f) on the proximal (10) side of the distribution inlet (110). The plurality of outlets (122a to f) is configured to counteract a reduction in outflow as the distance from the distribution inlet (110) increases in the longitudinal direction (L).

Classes IPC  ?

• A61M 25/00 - CathétersSondes creuses
• A61M 25/02 - Dispositifs de maintien en position, p. ex. sur le corps
• A61M 39/00 - Tubes, raccords ou accouplements pour tubes, soupapes, voies d'accès ou similaires, spécialement adaptés pour un usage médical
• A61M 39/10 - Raccords ou accouplements pour tubes

Abrégé

A method for forming a device coupon (100) includes providing a source wafer (1) with a source substrate (10); a sacrificial layer (11); and a film (12). At least one device coupon (100) is formed in the film (12). One or more designed breakable tethers is designed to secure the device coupon (100) to the film (12). The method includes etching one or more recesses (111) extending through the device coupon (100), thereby exposing the sacrificial layer (11); and etching the sacrificial layer (11) away at least partially through one or more of the recesses (111), thereby forming one or more sacrificial recesses (121) in the sacrificial layer (11). At least some pairs of recesses (111) and sacrificial recesses (121) are filled with a support material (200), thereby forming support structures (220) for device coupon (100).

Classes IPC  ?

• H01L 21/78 - Fabrication ou traitement de dispositifs consistant en une pluralité de composants à l'état solide ou de circuits intégrés formés dans ou sur un substrat commun avec une division ultérieure du substrat en plusieurs dispositifs individuels
• H01L 21/683 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitementAppareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants pour le maintien ou la préhension

Abrégé

The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/56 - IFN-alpha
• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to glycoside phosphorylases which are useful for the production of isomelezitose (α-D-glucopyranosyl-(1,6)-β-D-fructofuranosyl-(2,1)-α-D-glucopyranoside). More specifically, the invention relates to sucrose 6(F)-phosphate phosphorylases (EC 2.4.1.329), which catalyze, among other things, the synthesis of isomelezitose from a suitable glycoside donor and isomaltulose, where said glucosyl donor can be sucrose or α-D-glucose 1- phosphate. The present invention further relates to a method for producing isomelezitose using said sucrose 6(F)-phosphate phosphorylases.

Classes IPC  ?

• C12N 9/10 - Transférases (2.)
• C12P 19/00 - Préparation de composés contenant des radicaux saccharide

Abrégé

A method for manufacturing a textile connector patch for a textile connector, the method including: providing a first outer patch with a textile patch; applying a conductive patch on the first outer patch; placing a thermoplastic patch with a through-hole onto the conductive patch; inserting a connector wire between the conductive patch and the thermoplastic patch so that the wire is exposed through the through-hole; laminating the first outer patch, the conductive patch, and the thermoplastic patch together to form a laminated stack that clamps the connector wire; adding conductive resin into the through-hole; attaching a second outer patch with a textile patch onto the thermoplastic patch; and laminating all patches together to produce the textile connector patch; wherein, during lamination, the conductive resin deforms to establish a permanent connection between the connector wire and the conductive patch.

Classes IPC  ?

• A41D 31/04 - Matériaux spécialement adaptés aux vêtements de dessus caractérisés par une fonction ou une utilisation particulières
• B32B 3/26 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes
• B32B 5/02 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments
• B32B 27/12 - Produits stratifiés composés essentiellement de résine synthétique adjacente à une couche fibreuse ou filamenteuse
• B32B 27/40 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyuréthanes

Abrégé

An integrated electro-optic modulator (1) comprising: - an electro-optic layer (11) comprising an electro-optic material being a uniaxial material with an extraordinary axis (110), comprising at least: o a first region (101) in which the extraordinary axis (110) is oriented along a first direction (111); o a second region (102) in which the extraordinary axis (110) is oriented along a second direction (112) opposite to the first direction (111); - a first electrode (21); - a second electrode (22); - a first optical waveguide (31); and - a second optical waveguide (32); and wherein the first optical waveguide (31) and the second optical waveguide (32) are provided between the first electrode (21) and the second electrode (22) along the extraordinary axis (110).

Classes IPC  ?

• G02F 1/035 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des céramiques ou des cristaux électro-optiques, p. ex. produisant un effet Pockels ou un effet Kerr dans une structure de guide d'ondes optique
• G02F 1/03 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des céramiques ou des cristaux électro-optiques, p. ex. produisant un effet Pockels ou un effet Kerr
• G02F 1/225 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence dans une structure de guide d'ondes optique
• G02F 1/21 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence

Abrégé

Provided herein is a system (1000) for assisting a surgical intervention on a bone of a subject comprising: - a jig holder (100), JH, comprising at least one JH bracelet (112, 142) wherein each JH bracelet (112, 142) comprises: - a longitudinal JH bracelet body (114, 144) having a proximal end, a distal end, a central direction towards a central longitudinal axis (A-A'), and a peripheral direction away in a perpendicular direction from the central longitudinal axis (A-A'); - a JH passageway (116, 146) disposed in the JH bracelet body (114, 144) between the proximal end and the distal end, and having a shape complementary to a target region of the bone of the subject for the surgical intervention; - a JH coupling region (118, 148) comprising a ring of exterior surface of the JH bracelet body (114, 144) for repeatable dismountable coupling to and alignment with a jig (200); wherein each JH bracelet body (114, 144) has an assembled state (114ASM, 144ASM) and disassembled state (114DASM, 144DASM), wherein: - each JH bracelet body (114, 144) comprises a plurality of JH bracelet body segments (144a; 144b); - the plurality of JH bracelet body segments (144a; 144b) of each JH bracelet body (144) in the disassembled state (114DASM, 144DASM), co-operate to form the assembled state (114ASM, 144ASM) for a form-fit coupling by the JH passageway (116, 146) to the target region of the bone of the subject for the surgical intervention; wherein each JH bracelet body segment (144a; 144b) is a longitudinal segment of the JH bracelet body (114, 144).

Classes IPC  ?

• A61B 17/15 - Leurs dispositifs de guidage
• A61B 17/17 - Dispositifs de guidage pour les forets

Abrégé

The invention relates to the field of glycoprotein production means and methods. More specifically, the present invention provides for a novel yeast strain with a mutant Och1 gene resulting in modified N-glycosylation properties of said strain. Even more specifically, said mutant Och1 gene comprises a sequence coding for a mutant OCH1 protein in which one amino acid near the catalytic site, corresponding to position 151 of the OCH1 protein of the methylotrophic wild type Pichia pastoris strain, is deleted. More specifically, the use of said mutant yeast strain for recombinant expression of glycoproteins results in more homogenous mammalian-like N-glycan structures on said heterologously produced glycoproteins.

Classes IPC  ?

• C12N 1/16 - LevuresLeurs milieux de culture
• C12N 9/10 - Transférases (2.)
• C12P 21/00 - Préparation de peptides ou de protéines
• C12R 1/84 - Pichia

Abrégé

The present invention provides a method and a composition for increasing nitrogen fixation of at least one strain of a nitrogen fixing bacteria or acquisition of nitrogen for a plant in need thereof.

Classes IPC  ?

• C05F 11/08 - Engrais organiques comportant l'addition de cultures bactériennes, de mycélium ou similaires
• A01N 63/20 - BactériesSubstances produites par des bactéries ou obtenues à partir de celles-ci
• A01P 21/00 - Régulateurs de croissance des végétaux

Abrégé

A surface-emitting lasing device includes a substrate and an array of parallel nano-ridge devices grown epitaxially on the substrate. The nano-ridge devices are configured for together form a laser cavity that supports a slow light band-edge lasing mode for lasing across the array of nano-ridges and to couple the laser mode out from the substrate surface to enable surface emission.

Classes IPC  ?

• H01S 5/40 - Agencement de plusieurs lasers à semi-conducteurs, non prévu dans les groupes
• H01S 5/00 - Lasers à semi-conducteurs
• H01S 5/02 - Détails ou composants structurels non essentiels au fonctionnement laser

Abrégé

The present invention pertains to the field of targeted protein degradation (TPD) and target protein recruitment (TPR) providing a versatile platform for TPD, TPR and other applications dependent on cell surface ternary complex formation. In particular, the present invention provides a compound comprising a macromolecular hydrophilic polymer scaffold which is conjugated with several copies of at least two different protein binding ligands. The polymeric scaffold of the invention enables the use of small molecule ligands for target proteins of interest. Furthermore, the invention also relates to a composition comprising said polymeric scaffolds and uses thereof, e.g. for inhibiting or removing malignant or unwanted proteins; or for use in the targeted recruitment of effector cells such as CAR-T cells.

Classes IPC  ?

• A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

Provided herein is a method for predicting: a proxy evoked potential pattern, EP pattern (124'), and/or one or more proxy evoked potential parameters, proxy EP parameters (126'), of the EP pattern (124'), and/or one or more parameters derivable from the one or more proxy EP parameters, proxy dEP parameters (126'), the method comprising: receiving test electroencephalogram data, test EEG data, of the test subject containing at least one data segment, test FP EEG data segment, of the test EEG data, wherein the test FP EEG data segment is a portion of the test EEG data devoid of influence of an evoked potential, - determining from the at least one test FP EEG data segment, or one or more test FP EEG parameters determined from the FP EEG data segment, the proxy EP pattern, and/or the proxy EP parameter, and/or the proxy dEP parameter.

Classes IPC  ?

• A61B 5/327 - Génération de signaux ECG artificiels à partir de signaux mesurés, p. ex. pour pallier l’absence d’électrodes
• A61B 5/377 - Électroencéphalographie [EEG] utilisant des réponses provoquées
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

Provided is a system (100) for multiple-repeated deliveries of a dose of a liquid below an exterior surface of a skin of a subject comprising: a cartridge (200) comprising a needle assembly (120) comprising a needle assembly body (122) and a set (124) of one or more hollow needle(s) (125) attached to the needle assembly body (122), each needle having a lumen for delivery of the dose of the liquid; a dosing element (800), configured for providing the liquid to the set (124) of hollow needle(s) (125) according to a flow cycle (400), wherein the flow cycle is a variation in flow rate during a flow cycle duration (406) to the set of needles and comprises a period of maximum flow rate and a period of a minimum flow rate; - a liquid supply system (900) having an outlet in fluid connection with an inlet of the dosing element (800); a movement inducer (140) configured to induce slidable movement in the needle assembly body (122) according to a stroke cycle (300), wherein the stroke cycle (300) contains a pattern of motion (320) of the needle assembly body (122) within a stroke cycle duration (306) and the flow cycle (400) is synchronized with the stroke cycle (300); and a primary control unit (700) configured to control at least the flow cycle (400), the stroke cycle (300), and their synchronisation.

Classes IPC  ?

• A61M 5/482 -
• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
• A61M 5/46 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour commander la profondeur de pénétration
• A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique

Abrégé

The present invention relates to the field of producing long chain dicarboxylic acids, i.e. dicarboxylic acids having a chain length of 16 to 24 carbon atoms. Indeed, the present invention discloses genetically modified yeast strains which lack particular genes or gene products, and/or express or over-express particular genes, capable to produce significant amounts of long chain dicarboxylic acids instead of sophorolipids which are produced by their wild-type counterparts. Long chain dicarboxylic acids are valuable precursors for a variety of products such as high-grade polymers, plasticizers, coatings, corrosion inhibitors, adhesives, perfumes, or antibiotics.

Classes IPC  ?

• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/10 - Transférases (2.)
• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12P 7/6409 - Acides gras
• C12R 1/72 - Candida

Abrégé

A computer-implemented method for operating an assembly configuration system, the method comprising: receiving an input demand; receiving one or more datasets including data points each including data of the performance indicators and data of the therewith associated inputs, outputs, and sets of parameters; determining from the one or more datasets a combined set of values for the sets of parameters based on the input demand and on a desired combination of the performance indicators; configuring the sets of parameters by assigning the combined set of values thereto; and generating an execution plan as the second output based on the input demand and the configured sets of parameters A computer-implemented method for operating a reconfiguration assembly system.

Classes IPC  ?

• G06Q 10/06 - Ressources, gestion de tâches, des ressources humaines ou de projetsPlanification d’entreprise ou d’organisationModélisation d’entreprise ou d’organisation
• G06Q 50/04 - Fabrication
• G05B 19/418 - Commande totale d'usine, c.-à-d. commande centralisée de plusieurs machines, p. ex. commande numérique directe ou distribuée [DNC], systèmes d'ateliers flexibles [FMS], systèmes de fabrication intégrés [IMS], productique [CIM]

Abrégé

According to an aspect there is provided a contact lens system comprising: at least one magnet to be arranged at an eyelid of a subject for moving with the eyelid; a contact lens to be arranged on an eyeball, the contact lens comprising a loop antenna, wherein the loop antenna is to be arranged for intersecting with a magnet trajectory of the magnet, during a blink movement of the eyelid, wherein the magnet passes over at least one edge of the loop antenna, causing a change of magnetic flux through the loop antenna; a sensor for sensing at least one pulse during the blink movement in response to the change of magnetic flux through the loop antenna; and a processing unit configured to receive data from the sensor representing the pulse, and to analyze the data for determining a position of the contact lens with respect to the magnet trajectory of the magnet.

Classes IPC  ?

• G02C 7/04 - Lentilles de contact pour les yeux
• G02C 11/00 - Accessoires non optiquesFixation de ceux-ci
• A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil

Abrégé

The current invention relates to the field of in vitro culturing of T cells, more in particular of in vitro production of unconventional T cells expressing specific markers. Indeed, the present invention discloses a method to produce said unconventional T cells comprising the generation of hybrid spheroids out of combining stem cells and adherent cells and further culturing said spheroids at the air liquid interface. The latter T cells can be used to produce CAR-T cells.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/0789 - Cellules souchesCellules progénitrices multipotentes

Abrégé

Morphoregulator polypeptides that can be used to improve the capacity of the plant cells to regenerate embryogenic plant tissues, plant organs, and whole plants are disclosed. Also disclosed are plant cells comprising the polypeptides and related methods for improving the capacity of the plant cells to regenerate embryogenic plant tissues, plant organs, and whole plants.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01H 6/46 - Gramineae ou Poaceae, p. ex. ivraie, riz, blé ou maïs
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 9/22 - Ribonucléases

Abrégé

A composition includes particles for use in a method for the treatment of a vitreous disease or a vitreous disorder as a light sensitizing agent. Each particle has a surface selected for or adapted for providing mobility of the particle in the vitreous and for binding to collagen aggregates, such as floaters.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61F 9/008 - Procédés ou dispositifs pour la chirurgie de l'œil utilisant un laser
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 33/242 - OrSes composés
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments

Abrégé

The present invention relates to a method and compositions for optimized cytosolic delivery of active agents, in particular nucleic acids, using a specific class of cationic amphiphilic compounds. The method and compositions of the invention enhance intracellular release of the agents and can be used for the treatment of various disorders.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

A textile electrode has an inner side for contacting a skin surface and an outer side for bordering with an environment. The textile electrode includes a thermoplastic layer having a plurality of closed, air-filled cavities delineating protruding portions on the inner side of the electrode for contacting the skin surface; and a textile layer laminated to the thermoplastic layer towards the outer side of the textile electrode.

Classes IPC  ?

• B32B 27/12 - Produits stratifiés composés essentiellement de résine synthétique adjacente à une couche fibreuse ou filamenteuse
• B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
• B32B 27/08 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique d'une résine synthétique d'une sorte différente
• B32B 27/40 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyuréthanes
• B32B 37/20 - Procédés ou dispositifs pour la stratification, p. ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par les propriétés des couches toutes les couches existant et présentant une cohésion avant la stratification impliquant uniquement l'assemblage de bandes continues

Abrégé

The present invention generally relates to methods and systems for predicting one or more a kinetic biomarkers associated with one or more neurodevelopmental disorder, such as autism spectrum disorder, by monitoring and analysing various movement behaviours. Specifically, the present invention can be applied to monitor and record data on atypical movement behaviours, such as tiptoe behaviour and axis-spinning, when observed in subjects including children and adults. An aspect of the invention relates to a computer-implemented method for predicting a kinetic biomarker associated with a neurodevelopmental disorder; the method comprising: - receiving a first data flow indicative of a movement and orientation of the lower leg of the subject; - receiving a second data flow indicative of a movement and orientation of the foot of the subject; - determining using at least one machine learning model that the first data flow and second data flow correspond to an atypical movement event; - determining, based on a frequency of occurrence of the atypical movement event during a predetermined time window, that the first data flow and the second data flow correspond to at least one kinetic biomarker associated with the neurodevelopmental disorder; and, - generating a report comprising the kinetic biomarker.

Classes IPC  ?

• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local

Abrégé

A system for monitoring effector cell mediated killing of target cells includes a containment unit with multiple discrete confinement locations, each capable of simultaneously holding at least one effector cell and one target cell. The system also features a lens-free imaging module for capturing images of all cells within the containment unit and a control unit configured to operate the imaging module to capture a sequence of images over time, extract features from these images, and monitor the effector cell mediated killing of the target cells.

Classes IPC  ?

• C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
• C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores

Abrégé

An amplifier (100) is provided for amplifying a complex input communication signal (109) having an in-phase and quadrature component. The amplifier has a modulation circuitry (110) configured to convert the input signal to quantized samples (111) by performing oversampling, where the quantized samples represent a finite set of constellation points; and a phase mapping circuitry (120) configured to map the quantized samples onto two constant-envelope phase-modulated signals (121, 122) selected from a finite set of constant-envelope phase-modulated signals (172, 221-224) having a carrier frequency fc (171) and (different) constant phases. A first and second power amplifier (130, 140) is configured to amplify the two constant-envelope phase-modulated signals by a gain G; and a combiner (150) is configured to combine the two amplified constant-envelope phase-modulated signals (131, 141) thereby obtaining a complex output communication signal (151) with the carrier frequency fc representing an amplification (161) of the complex input communication signal (109).

Classes IPC  ?

• H03F 1/02 - Modifications des amplificateurs pour augmenter leur rendement, p. ex. étages classe A à pente glissante, utilisation d'une oscillation auxiliaire
• H03F 3/24 - Amplificateurs de puissance, p. ex. amplificateurs de classe B, amplificateur de classe C d'étages transmetteurs de sortie

Abrégé

The present invention relates to an adenine base editor (ABE), and components thereof. The present invention also relates to a complex comprising an adenine base editor (ABE) and a guide RNA in a functionally associated form. The present invention further relates to a nucleic acid molecule encoding the ABE/guide RNA, an expression construct or a vector comprising a nucleic acid sequence encoding the adenine base editor and/or the nucleic acid sequence encoding the guide RNA. The present invention further relates to a cell comprising an adenine base editor (ABE) and a method of adenine base editing of a target site in a genome of interest in at least one cell of a prokaryotic organism, including bacterial and archaeal organisms, or eukaryotic organism. Besides that, the present invention relates to various methods, kits and uses associated with the ABEs provided.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 9/22 - Ribonucléases
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées

Abrégé

A computer-implemented method for scheduling audio streams (120, 121, 122, 123, 124, 130, 131) within a wireless digital audio system (1) comprising a central unit (100), audio sinks (115-117, 125-129) and audio sources (125-129); wherein the central unit is configured to determine a broadcasting time schedule (101) for isochronous operation of the wireless digital audio system, wherein the broadcasting time schedule comprises consecutive time intervals (102, 103, 104); wherein a time interval comprises a set of time slots (110, 111, 112); the method comprising: broadcasting, by the central unit, one or more audio streams in one or more time slots of the set of time slots; and delegating, by the central unit, upon request of an audio source (125), the broadcasting in a subset (111) of the set of time slots to the audio source.

Classes IPC  ?

• H04L 65/403 - Dispositions pour la communication multipartite, p. ex. pour les conférences
• H04L 65/611 - Diffusion en flux de paquets multimédias pour la prise en charge des services de diffusion par flux unidirectionnel, p. ex. radio sur Internet pour la multidiffusion ou la diffusion
• H04W 72/0446 - Ressources du domaine temporel, p. ex. créneaux ou trames
• H04W 72/121 - Planification du trafic sans fil pour les groupes de terminaux ou d’utilisateurs
• H04W 72/1263 - Jumelage du trafic à la planification, p. ex. affectation planifiée ou multiplexage de flux
• H04L 65/80 - Dispositions, protocoles ou services dans les réseaux de communication de paquets de données pour prendre en charge les applications en temps réel en répondant à la qualité des services [QoS]
• H04W 4/80 - Services utilisant la communication de courte portée, p. ex. la communication en champ proche, l'identification par radiofréquence ou la communication à faible consommation d’énergie

Abrégé

The present disclosure relates to the field of biomechanical motion modelling and simulation of an anatomical body, specifically to the development and implementation of methods for analysing, predicting, and simulating movement of anatomical structures. This methods described in the present disclosure finds applications in various industries, including medical research, biomechanics, robotics, and animation, where modelling of anatomical dynamics is relevant. An aspect of the present invention relates to a computer-implemented method comprising the steps of: - obtaining a plurality of anatomical models; - defining anatomical features on the plurality of anatomical model; - defining a target distance of separation between the anatomical models; - determining a transformation factor for aligning the anatomical models; - applying the transformation factors to reposition the anatomical models; and, - iteratively refining the transformation factors.

Classes IPC  ?

• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G06N 3/00 - Agencements informatiques fondés sur des modèles biologiques
• G06N 20/00 - Apprentissage automatique
• G06T 7/20 - Analyse du mouvement
• G06T 13/20 - Animation tridimensionnelle [3D]
• G06T 17/00 - Modélisation tridimensionnelle [3D] pour infographie
• G09B 23/00 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration
• G09B 23/10 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la physique pour la statique ou la dynamique des corps solides
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition

Abrégé

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

Classes IPC  ?

• C07K 14/525 - Facteur de nécrose de tumeurs [TNF]
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes

Abrégé

Nucleoside analogues and compositions containing said nucleoside analogues are provided, according to a general formula (I) disclosed herein. Processes are provided for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.

Classes IPC  ?

• C07H 19/14 - Radicaux pyrrolo-pyrimidine
• A61K 31/7064 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées
• A61P 33/00 - Agents antiparasitaires
• C07H 19/23 - Radicaux hétérocycliques contenant au moins deux hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, non prévus dans les groupes

Abrégé

The invention relates to a method for layer-by-layer deposition of concrete, in particular of concrete using a rapidly hydrating cementitious binder. The invention relates to a method for layer-by-layer deposition of concrete, in particular of concrete using a rapidly hydrating cementitious binder. A first flow and a second flow are supplied to a mixer to obtain extrudable concrete. The pH of the second flow is larger than the pH of the first flow. The first flow comprises a retarded cementitious binder obtainable by mixing a cementitious binder with a retarder comprising boron and sodium. The retarder allows to increase the setting time of the cementitious binder and allows to influence the pH of the first flow in such a way that the pH of the first flow is lower than the pH of a flow equal to the first flow but comprising the cementitious binder instead of the retarded cementitious binder. The second flow comprises a carrier material. The volume fraction of the carrier material is at least 20 vol % of the second flow. The invention relates to a method for layer-by-layer deposition of concrete, in particular of concrete using a rapidly hydrating cementitious binder. A first flow and a second flow are supplied to a mixer to obtain extrudable concrete. The pH of the second flow is larger than the pH of the first flow. The first flow comprises a retarded cementitious binder obtainable by mixing a cementitious binder with a retarder comprising boron and sodium. The retarder allows to increase the setting time of the cementitious binder and allows to influence the pH of the first flow in such a way that the pH of the first flow is lower than the pH of a flow equal to the first flow but comprising the cementitious binder instead of the retarded cementitious binder. The second flow comprises a carrier material. The volume fraction of the carrier material is at least 20 vol % of the second flow. The present invention also relates to a bicomponent cementitious binder composition comprising a first component comprising rapidly hydrating cementitious material.

Classes IPC  ?

• B28B 1/00 - Fabrication d'objets façonnés à partir du matériau
• B28C 7/04 - Alimentation ou dosage des ingrédients
• B33Y 10/00 - Procédés de fabrication additive
• B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
• C04B 22/00 - Emploi de matières inorganiques comme ingrédients actifs pour mortiers, béton ou pierre artificielle, p. ex. emploi d'accélérateurs
• C04B 28/06 - Ciments alumineux
• C04B 40/06 - Inhibition de la prise, p. ex. pour mortiers du type à action différée contenant de l'eau dans des récipients frangibles
• C04B 111/00 - Fonction, propriétés ou utilisation des mortiers, du béton ou de la pierre artificielle
• E04G 21/04 - Dispositifs pour transporter et distribuer en même temps

Abrégé

Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-COV-2, including SARS-COV-2 variants, and SARS-COV. 1. The binding agents, in particular the antibodies and antibody fragments, bind to heptad repeat 2 (HR2) domain of spike protein of the Sarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. Also disclosed are methods using these binding agents and uses thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention generally relates to a method for preparing polyalkyleneimines, and to polyalkyleneimines obtainable by the method. The present invention further relates to particular polyalkyleneimines, and to the use of the polyalkyleneimines in human or veterinary medicine.

Classes IPC  ?

• C08G 73/02 - Polyamines

Abrégé

Described herein is a composition comprising two or more bacterial strains belonging to at least two of the following genera: Faecalibacterium, Butyricicoccus, Roseburia, Akkermansia, Lactiplantibacillus or Anaerostipes. Aspects described herein may be used in the treatment of a disease or condition of the liver, a symptom thereof.

Classes IPC  ?

• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 9/12 - Antihypertenseurs

Abrégé

The present invention relates to binding agents specifically binding to the folate transport complex. More specifically, antibodies or antibody fragments including immunoglobulin single variable domain (ISVD) antibodies are disclosed that bind the human folate receptor alpha (hFOLRα) present at the choroid plexus epithelial cells. The invention further relates to the antibodies and the methods herein described for use to increase the delivery of pharmaceutical compounds to the central nervous system via the process of receptor mediated endocytosis and/or transcytosis.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention relates to a method to prepare a composition comprising an epoxy-based covalent adaptable network. The invention relates to a method to prepare a composition comprising an epoxy-based covalent adaptable network. The method comprises the steps of a) contacting a compound A and a compound B in controlled amounts to obtain a mixture comprising a curing agent. The compound A has a′ functional groups of the type —C(═O)ORx and/or of the type —C(═O)— with the a′ functional groups being arranged in pairs, positioned at a controlled distance from each other. The compound B has b′ primary amine functional groups with the b′ primary amine functional groups being arranged in pairs, positioned at a controlled distances from each other. b) contacting the mixture obtained in step a) with at least one compound C having epoxide functional groups to obtain the epoxy-derived covalent adaptable network. The invention relates to a method to prepare a composition comprising an epoxy-based covalent adaptable network. The method comprises the steps of a) contacting a compound A and a compound B in controlled amounts to obtain a mixture comprising a curing agent. The compound A has a′ functional groups of the type —C(═O)ORx and/or of the type —C(═O)— with the a′ functional groups being arranged in pairs, positioned at a controlled distance from each other. The compound B has b′ primary amine functional groups with the b′ primary amine functional groups being arranged in pairs, positioned at a controlled distances from each other. b) contacting the mixture obtained in step a) with at least one compound C having epoxide functional groups to obtain the epoxy-derived covalent adaptable network. The invention further relates to compositions obtainable by such method.

Classes IPC  ?

• C08G 59/58 - Amines en mélange avec d'autres agents de durcissement avec des acides polycarboxyliques ou leurs anhydrides, halogénures ou esters à bas poids moléculaire

Abrégé

The invention relates to the field of cell surface display and selection of Fc-containing molecules such as antibodies or alike, and/or selection of Fc-containing molecule-expressing clones. In particular, the invention relates to a method for displaying Fc-containing proteins on a cell, in particular wherein said method further relates to selection of yeast clones recombinantly expressing Fc-containing proteins. The invention further relates to a capturing or binding agent comprising a Fc-binding protein and an oligomannose binding protein, wherein the oligomannose binding protein specifically binds oligomannose or mannan on the outside of a cell, in particular a yeast cell. In particular, the invention discloses a binding agent comprising a bivalent ZZ domain or an antigen-binding domain specifically binding to Fc-tails, and comprising a lectin domain, wherein the lectin preferably binds yeast mannans. The invention further relates to a method for cell surface display of Fc-containing proteins wherein the capturing agent is applied to a population of cells to connect the cell surface via oligomannose-binding to the secreted Fc-containing proteins recombinantly expressed by said cell. In particular, the invention relates to said method further used to isolate the cells with the highest number of secreted Fc- containing proteins by cell sorting of the displayed cells.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/42 - Lectines, p. ex. concanavaline, phytohémagglutinine
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C12R 1/84 - Pichia

Abrégé

An optical frequency comb device includes: an optical waveguide; a first mirror disposed at a first position in the optical waveguide; a second mirror disposed at a second position different from the first position, in the optical waveguide; a gain medium and a saturable absorber which are disposed between the first mirror and the second mirror; and a controller that fixes one of a repetition frequency and a carrier-envelope offset frequency of an optical frequency comb output from an end of the optical waveguide, and changes the other of the repetition frequency and the carrier-envelope offset frequency.

Classes IPC  ?

• G02F 1/025 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments à semi-conducteurs ayant des barrières de potentiel, p. ex. une jonction PN ou PIN dans une structure de guide d'ondes optique
• G01S 17/34 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes continues, soit modulées en amplitude, en fréquence ou en phase, soit non modulées utilisant la transmission d'ondes continues modulées en fréquence, tout en faisant un hétérodynage du signal reçu, ou d’un signal dérivé, avec un signal généré localement, associé au signal transmis simultanément
• G02F 1/015 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments à semi-conducteurs ayant des barrières de potentiel, p. ex. une jonction PN ou PIN
• G02F 2/00 - Démodulation de la lumièreTransfert de la modulation de la lumière moduléeChangement de fréquence de la lumière
• H01S 5/02 - Détails ou composants structurels non essentiels au fonctionnement laser
• H01S 5/042 - Excitation électrique
• H01S 5/0625 - Dispositions pour commander les paramètres de sortie du laser, p. ex. en agissant sur le milieu actif en faisant varier le potentiel des électrodes dans des lasers à plusieurs sections
• H01S 5/065 - Accrochage de modesSuppression de modesSélection de modes
• H01S 5/10 - Structure ou forme du résonateur optique
• H01S 5/14 - Lasers à cavité externe

Abrégé

Method for interconnecting integrated circuit modules of a semiconductor system, each integrated circuit module comprising at least one processing unit, each processing unit comprising at least one optical device. The method comprises: providing a photonics layer in optical communication with the optical devices and comprising optical interconnections; providing the semiconductor system on top of the photonics layer; in the semiconductor system, defining a plurality of cells, each comprising at most one processing unit from each of the integrated circuit modules; each of the processing units is comprised in at most one of the cells; and in the photonics layer, for each of the cells, providing an optical interconnection between one optical device of one of the processing units of the cell and one optical device of at least another processing unit of the same cell for coupling between the optical devices.

Classes IPC  ?

• G02B 6/43 - Dispositions comprenant une série d'éléments opto-électroniques et d'interconnexions optiques associées
• G06F 30/394 - Routage
• H04B 10/80 - Aspects optiques concernant l’utilisation de la transmission optique pour des applications spécifiques non prévues dans les groupes , p. ex. alimentation par faisceau optique ou transmission optique dans l’eau
• G06F 111/12 - Schématique symbolique
• G06F 113/18 - Positionnement de puces
• G06F 115/12 - Cartes de circuits imprimés [PCB] ou modules multi-puces [MCM]
• G06F 117/02 - Tolérance aux défaillances, p. ex. pour la suppression de défaillances transitoires

Abrégé

Example embodiments describe a CDR, circuitry (400) for sampling a burst serial data signal (401) characterized by a data symbol period; the burst serial data signal containing at least a preamble and data portion (401b); the CDR circuitry is configurable in a first mode (403a) for detecting (440) a sampling position when receiving the preamble portion, and in a second mode (403b) for sampling (410) the data portion. The CDR comprises i) a sampling circuitry (410) to sample the signal by at least one sampling clock (404); ii) a sampling clock generator (450) to generate from a reference clock signal (405) with a configurable phase shift (408) one first and one second sampling clock (404a, 404b) for sampling the burst serial data signal by the sampling circuitry when in the respective first and second mode, and to generate the second sampling clock (404b) for sampling times per data symbol period, and to generate the first sampling clock (404a) such that the sampling circuitry samples different sampling positions within an equivalent data symbol period during data symbol periods by adjusting the sampling period of the at least one first sampling clock signal by a sampling offset,, during the sampling of the data symbol periods; and iii) an edge detection circuitry (440) configured to, in the first mode, determine a sampling position from the sampled predefined pattern, and configured to derive the configurable phase shift from the determined sampling position and the applied sampling offset.

Classes IPC  ?

• H04L 7/00 - Dispositions pour synchroniser le récepteur avec l'émetteur
• H03L 7/00 - Commande automatique de fréquence ou de phaseSynchronisation

Abrégé

222-OH, with R comprising a C1-C10 alkyl or an aryl, with the alkyl or aryl being substituted or non-substituted.

Classes IPC  ?

• C09D 9/00 - Produits chimiques pour enlever la peinture ou l'encre
• B29B 17/02 - Séparation de matières plastiques des autres matières
• C08J 11/08 - Récupération ou traitement des résidus des polymères sans réaction chimique utilisant des solvants sélectifs des constituants polymères

Abrégé

Clostridium luticellariiClostridium luticellarii in order to convert a carbohydrate and/or lactic acid into isobutyric acid and/or isobutanol and presents the process sequence. The latter compounds can be applied in animal feed and food, as flavor ingredient, as pharmaceutical compound, as plastic precursor.

Classes IPC  ?

• C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
• C12P 7/16 - Butanols
• C12P 7/52 - Acide propioniqueAcides butyriques
• C12P 7/54 - Acide acétique
• C12P 7/56 - Acide lactique
• C12R 1/145 - Clostridium

Abrégé

CooperiaCooperia.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Produits et services

Arranging and conducting of conferences, congresses and symposiums; Arranging and conducting of commercial, trade and business conferences; Seminars; Arranging, conducting and organisation of workshops; Organisation of Webinars; Arranging and conducting of lectures; University services; University education services; Education and instruction services; Publishing, reporting, and writing of texts; Publishing of scientific papers; Publication of instructional literature; Publishing of medical publications; Ticket reservation and booking services for education, entertainment and sports activities and events. Science and technology services; Medical and pharmacological research services; Scientific research and analysis; Engineering services; Veterinary research; Provision of information and data relating to medical and veterinary research and development; Animal genetics research; Veterinary laboratory services.

Abrégé

The present invention relates to a method and composition for prevention and treatment of infections in a subject, in particular, with intracellular bacteria. The invention provides an optimized intracellular delivery of an active agent, in particular, a nucleic acid, using a nanoparticle formulation including an iNKT cell agonist.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/04 - Agents antibactériens

Abrégé

Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• C07K 14/81 - Inhibiteurs de protéase
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to antimicrobial peptides comprised of a first domain with activity specific to a peptidoglycan or component thereof; a second domain with activity specific to an ester linkage; and a third domain with membrane permeabilising activity. The invention also relates to the use of such peptides in medicine, for example for treating mycobacterial infection.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/46 - Hydrolases (3)
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
• C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques

Abrégé

A medical implant (100) for treatment of one or more fractures of a scapula (200) of a subject, comprises: a longitudinal body (18) having a medial end (10) and a lateral end (12), a cranial side (14), and an caudal side (16); a scapular spine portion (SSP) (20) of the longitudinal body (18), located at the medial end (10), having an SSP co-operating surface (22) configured for co-operation with a scapular spine (220) of the subject; an acromion portion (AP) (60) of the longitudinal body (18), located at the lateral end (16), having an AP co-operating surface (62) configured for co-operation with a caudal surface (212) of the acromion (210) of the subject; and bridging portion (40) of the longitudinal body (18) connecting the scapular spine portion (SSP) (20) to the acromion portion (AP) (60), and configured to maintain the scapular spine portion (SSP) (20) in fixed positional relation with the acromion portion (AP) (60); wherein the SSP (20) co-operating surface (22) is deposed on the caudal side (16) and the AP (60) co-operating surface (62) is disposed on the cranial side (14) of the implant (100).

Classes IPC  ?

• A61B 17/80 - Plaques corticales

Abrégé

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor, more specifically agents comprising an immunoglobulin single variable domain (ISVD) which allow internalisation upon binding to the extracellular N-terminal domains 1, 2 and/or 3 in monovalent format. More specifically said ISVD provides for means and methods for lysosomal targeting, especially when fused to further proteins such as enzymes relevant for treatment of diseases caused by a lysosomal storage phenotype or lysosomal storage diseases. Finally the binding agents of the invention provide for use in therapeutic treatments, such as in Enzyme-replacement therapy, more specifically, when fused to human acid α-glucosidase (hGAA) or human cathepsin D proteases for treatment of Pompe disease or sporadic inclusion body myositis or neuronal ceroid lipofuscinosis 10 (CLN10), respectively.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The invention concerns a self-amplifying ribonucleic acid (saRNA) or trans-amplifying ribonucleic acid (taRNA) comprising: an alphavirus genomic 5' untranslated region (5'UTR) or mutant thereof; a nucleic acid sequence encoding alphavirus nonstructural proteins nsP1-4 or mutant thereof; an alphavirus sub-genomic promoter or mutant thereof; and (i) an open reading frame sequence encoding a protein of interest or (ii) a non-coding RNA of interest, wherein the alphavirus genomic 5'UTR or mutant thereof comprises one or more polynucleotide inserts downstream of a nucleotide at position -16, wherein the last nucleotide of the genomic 5' UTR is position -1, and wherein the length of the combined polynucleotide inserts is at least 5 nucleotides.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

This invention provides methods for the production of glycosylated triterpenoids which function as endosomal escape enhancers. Specifically, the invention provides UDP glycosyltransferases (UGTs) useful for the biosynthesis of these glycosylated triterpenoid saponins. The invention also provides in vitro systems and plant extracts comprising UDP glycosyltransferases and sapofectosid precursors.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits

Abrégé

The present invention relates to the use of a known enzyme ‘denominated as a Starmerella bombicola lactone esterase (Sble)’ to perform a transesterification and/or hydrolysis reaction. More specifically the Sble enzyme performs a transesterification and/or hydrolysis reaction on bola amphiphilic glycolipids. The invention indeed discloses that said Sble is capable to convert bola sophorolipids into lactonic and/or acidic sophorolipids and saccharides, and, that yeast strains containing a non-functional or dysfunctional Sble enzyme and/or a disabled sble gene and/or not containing the sble gene produce (acetylated) bola amphiphilic glycolipids. In addition, the invention further discloses a method to produce non-acetylated (bola) amphiphilic glycolipids via rendering acetyltransferase enzymes At1, At2 and At3 non-functional or dysfunctional in the latter yeast strains and/or by modifying strains so that they do not contain the acetyltransferase αt1, αt2 and αt3 gene(s) and/or by strains not containing the αt1, αt2 and αt3 gene(s). Moreover, upon rendering the glucosyltransferase B (UgtB1) non-functional or dysfunctional in the abovementioned strains and/or upon removing and/or disabling the ugtB1 gene and/or by strains not containing the ugtB1 gene these produce acetylated and/or non-acetylated bola amphiphilic glucolipids. The invention further discloses a method to produce non-acetylated glycolipids via rendering acetyltransferase enzymes At1, At2 and/or At3 non-functional or dysfunctional and/or removing and/or disabling the glycolipid acetyltransferase genes in glycolipid producing yeast strains and/or by strains not containing the αt1, αt2 and αt3 gene(s).

Classes IPC  ?

• C12N 1/16 - LevuresLeurs milieux de culture
• C12N 9/10 - Transférases (2.)
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12P 19/44 - Préparation d'O-glucosides, p. ex. glucosides
• C12R 1/72 - Candida

Abrégé

The present invention relates to the field alcohol intoxication and its treatment and discloses novel hybrid materials and pharmaceutical compositions, their manufacturing, and their use in the context of excessive alcohol consumption. The hybrid materials disclosed comprise (a) amyloid proteins, such as fibrous amyloid proteins, and (b) a multitude of single-site iron coordinated to said amyloid proteins. These hybrid materials may be converted to hydrogels, pharmaceutical compositions comprising such hydrogels, and oral dosage forms comprising such hydrogels. Further disclosed are methods for manufacturing such hybrid material and hydrogels as well as methods of using such hybrid materials and hydrogels in the treatment of alcoholism.

Classes IPC  ?

• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/02 - Composés inorganiques
• A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool

Abrégé

A method is for associating a prospective end node to an access point operating according to a wireless time-sensitive networking, W-TSN, mechanism by allocating time slices within a time cycle relative to a time reference to respective associated end nodes. The method includes: i) transmitting, by the access point, beacon frames including: as the time reference, a timestamp when the beacon frame is generated; and pre-schedule information identifying an association time slice within the time cycle relative to the time reference, during which prospective end nodes can exchange frames with the access point for associating; ii) by the prospective end node, receiving the beacon frames; pre-synchronizing with the access point based on the timestamp in at least one of the beacon frames; and identifying the association time slice within the time cycle based on the pre-schedule information; and iii) performing the associating within the association time slice.

Classes IPC  ?

• H04W 56/00 - Dispositions de synchronisation
• H04J 3/06 - Dispositions de synchronisation

Abrégé

The present invention provides chimeric genes and constructs which can be used to alter the lignin composition of woody plants and increase the saccharification and pulping efficiency of said plants. Particularly the lignin composition is modified by the incorporation of scopoletin.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)

Abrégé

The disclosed technology generally relates to an electro-optical device based on III-V and/or II-VI and/or group IV semiconductors. In one aspect, the electro-optical device includes a support region and a ridge structure extending from the support region. The ridge structure includes a bottom region provided on the support region and having at least one layer of a first semiconductor material that has a first conductivity type. The ridge structure also includes an intermediate region provided on the bottom region and having an active region. The intermediate region further includes at least one layer of a second semiconductor material, and has a trapezoid-shaped top region with a top surface, side surfaces, and inclined surfaces connecting the top surface to the side surfaces. The ridge structure also includes a capping layer provided on the side surfaces and the inclined surfaces of the intermediate region and having at least one layer of a third semiconductor material that has a higher band-gap than the second semiconductor material. The ridge structure also includes a fin structure extending upwards from the top region and having at least one layer of a fourth semiconductor material that has a second conductivity type.

Classes IPC  ?

• G02F 1/017 - Structures avec une variation de potentiel périodique ou quasi périodique, p. ex. superréseaux, puits quantiques

Abrégé

The current invention relates to a photoporated T cell, and wherein the homeostasis of said T cell after photoporation is unaffected and comparable to the homeostasis prior to said photoporation or compared to a non-photoporated T-cell. The invention further relates to a population of T cells and a pharmaceutical composition comprising a therapeutically effective amount of T cells.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to antigen-binding polypeptides specifically binding neuraminidase and/or haemagglutinin protein from Influenza B virus resulting in broadly neutralizing IBV antigen-binding polypeptides or antibodies. More specifically the invention relates to immunoglobulin single variable domains specifically binding NA or HA, which upon fusion to bispecific antigen-binding proteins provide for a broader and improved neutralization capacity as compared to a combination of IBV NA- and HA- targeting ISVDs or antibodies. The invention further relates to the use of said antigen-binding proteins for medical purposes, more specifically in prophylactic or therapeutic treatment of a subject, even more specifically to prevent or treat IBV infections.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

N-Aminoguanidine derivatives according to Formula (1), pharmaceutical compositions containing them and their use in the treatment of cancer.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07D 233/44 - Atomes d'azote ne faisant pas partie d'un radical nitro
• C07D 233/88 - Atomes d'azote, p. ex. allantoïne
• C07D 239/18 - Atomes d'azote ne faisant pas partie d'un radical nitro avec des hétéro-atomes liés auxdits atomes d'azote, à l'exception des radicaux nitro, p. ex. radicaux hydrazine
• C07D 243/04 - Composés hétérocycliques contenant des cycles à sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle les atomes d'azote étant en positions 1, 3
• A61K 31/4168 - 1,3-Diazoles ayant un atome d'azote lié en position 2, p. ex. clonidine
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime

Abrégé

This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV- 1, and affinity matured variants thereof. The binding agents, in particular the antibodies and antibody fragments, have one or more favourable antibody development characteristics. The invention also relates to methods using these binding agents and uses thereof.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

Bifunctional modified biopolymer based polymer comprise at least one polymer chain comprising n first functional groups and m second functional groups. The first functional groups comprise groups able of being radically cross-linked following a free radical chain-growth polymerisation. The second functional groups comprise groups able to thiol-ene crosslinking. Preferred bifunctional modified biopolymer based polymers comprise bifunctional modified gelatin and bifunctional modified collagen. The invention further relates to a method to prepare such a bifunctional modified biopolymer based polymer and to a method to prepare a hydrogel starting from such bifunctional modified biopolymer based polymer. Furthermore the invention relates to hydrogels obtainable starting from such bifunctional modified biopolymer based polymers and to the use of such hydrogels.

Classes IPC  ?

• C08H 1/06 - Produits macromoléculaires dérivés des protéines dérivés de corne, sabots, cheveux, cuirs ou peaux
• A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C08J 3/075 - Gels macromoléculaires

Abrégé

S.SSS.S.SS.S.S. bombicola SBLE enzyme and uses thereof for designing mutants with modulated hydrolytic and/or transesterification activity.

Classes IPC  ?

• C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
• C12P 19/44 - Préparation d'O-glucosides, p. ex. glucosides
• C12P 7/6436 - Esters d'acides gras
• G01N 33/483 - Analyse physique de matériau biologique

Abrégé

The present disclosure relates to the use of a polymer as chemical admixture, in particular, as superplasticizer, in a cementitious material. The polymer has a backbone structure provided with a plurality of negatively charged groups and provided with a plurality of side chains. at least part of the side chains comprises a pendent group having a sterically hindered amine. The disclosure further relates to a cementitious composition comprising a chemical admixture, in particular, a superplasticizer.

Classes IPC  ?

• C04B 24/26 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
• C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ

Abrégé

An optoelectronic device (100) comprises a semiconductor light-emitting component (101) capable of emitting light at a first wavelength, a cavity (107) filled with a semiconductor wavelength conversion material (103) disposed in a path of the light emitted by the semiconductor light-emitting component (101) for converting the first wave-length into a second wavelength and a first multilayer interference reflector (105) provided at a bottom of the cavity (107) directed to the light-emitting component (101). The first multilayer interference reflector (105) is configured to be transmitive for the first wavelength and reflective for the second wavelength and a second multilayer interference reflector (106) is provided at a top (106′) and sidewalls (106″) of the cavity (107). The second multilayer interference reflector (106) is configured to be transmitive for the second wavelength and to be reflective for the first wavelength. An associated method of making the optoelectronic device is also provided.

Classes IPC  ?

• H10H 20/851 - Moyens de conversion de la longueur d’onde
• B82Y 20/00 - Nano-optique, p. ex. optique quantique ou cristaux photoniques
• H01L 25/075 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant tous d'un type prévu dans une seule des sous-classes , , , , ou , p. ex. ensembles de diodes redresseuses les dispositifs n'ayant pas de conteneurs séparés les dispositifs étant d'un type prévu dans le groupe
• H10H 20/01 - Fabrication ou traitement
• H10H 20/814 - Corps ayant des moyens réfléchissants, p. ex. des réflecteurs de Bragg en semi-conducteurs
• H10H 29/30 - Affichages LED à matrice active

Abrégé

Method for deinking and/or delaminating of a plastic material, preferably a method for deinking and delaminating a plastic material in a single step. The method comprises contacting the plastic material with a deep eutectic solvent (DES) and an organic solvent at a temperature below 100°C to form a mixture, wherein the volume ratio of the organic solvent and the deep eutectic solvent in the mixture is at least 10:90.

Classes IPC  ?

• B29B 17/02 - Séparation de matières plastiques des autres matières
• B29L 9/00 - Produits stratifiés

Abrégé

The present invention relates to a crosslinked polymer material detectable by non-invasive imaging, comprising a biocompatible polymeric backbone comprising primary groups, linker groups, and imaging groups; wherein at least part of the primary groups are covalently bonded to the linker groups; and wherein at least part of the imaging groups are covalently bonded to each other and/or to one or more of the linker groups. The present invention further relates to a method to prepare said crosslinked polymer material, and uses of said crosslinked polymer material in biomedical applications such as biofabrication, tissue engineering, and medical devices.

Classes IPC  ?

• A61K 49/14 - Peptides, p. ex. protéines
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
• A61L 15/00 - Aspect chimique des bandages, des pansements ou des garnitures absorbantes ou utilisation de matériaux pour leur réalisation
• A61L 27/22 - Polypeptides ou leurs dérivés
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques

Abrégé

The present invention relates to a crosslinked polymer material detectable by radiological imaging (radiography or radiology), in particular X-ray imaging, radiography, computed tomography, sciascopy, sciagraphy, comprising a biocompatible polymeric backbone comprising primary groups, linker groups, and radiodense imaging groups; wherein at least part of the primary groups are covalently bonded to the linker groups; and wherein at least part of the imaging groups are covalently bonded to each other and/or to one or more of the linker groups. The present invention further relates to a method to prepare said crosslinked polymer material, and uses of said crosslinked polymer material in biomedical applications such as biofabrication, tissue engineering, and medical devices.

Classes IPC  ?

• A61K 49/04 - Préparations de contraste pour rayons X
• A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
• A61L 27/22 - Polypeptides ou leurs dérivés
• A61L 27/52 - Hydrogels ou hydrocolloïdes
• A61L 15/00 - Aspect chimique des bandages, des pansements ou des garnitures absorbantes ou utilisation de matériaux pour leur réalisation

Abrégé

The present invention relates to a computer-implemented method for emulating cochlear processing of auditory stimuli, the method comprising the steps of: - providing a multi-layer temporal convolution network (TCN), the network comprising: a. a plurality of stacked memory blocks, each memory block comprising at least one pointwise convolution and at least one depthwise convolution with a dilation factor; b. at least one nonlinear unit for applying a nonlinear transformation to the activation maps generated by at least one convolutional layer of the network; c. a plurality of residual and/or skip connections between the plurality of memory blocks, configured for forwarding the output of lower layer number memory blocks to at least one higher layer number memory block; d. an input layer, configured for receiving an input sequence to the network; and, e. an output layer, configured for generating for each input to the network, N output sequences of cochlear response parameters; - providing at least one input sequence of any length, wherein the input sequence is indicative of a time-sampled auditory stimulus; and, - applying the at least one input sequence to the input layer of the neural network to obtain the N output sequences of cochlear response parameters.

Classes IPC  ?

• G06N 3/0464 - Réseaux convolutifs [CNN, ConvNet]
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
• H04R 25/00 - Appareils pour sourds

Abrégé

Example embodiments relate to a method for performing a hand-over of a travelling end node associated to an initial access point in a wireless network. The wireless network comprises access points that operate according to a wireless time-sensitive networking mechanism by having allocated schedules with time slots for exchanging data with respective end nodes. The wireless network is managed by a network controller configured to allocate the schedules, and to perform the steps of determining one or more candidate access points; selecting a target access point; allocating a target time slot for exchanging data with the travelling end node within the schedule of the target access point avoiding time slots of the target access point that are allocated to other end nodes; determining a hand-over time; and providing to the travelling end node the hand-over time, an identifier of the target access point, and the target time slot.

Classes IPC  ?

• H04W 36/00 - Dispositions pour le transfert ou la resélection
• H04W 36/20 - Exécution d'une resélection à des fins spécifiques pour optimiser le niveau d’interférence
• H04W 36/08 - Resélection d'un point d'accès
• H04W 84/12 - Réseaux locaux sans fil [WLAN Wireless Local Area Network]

Abrégé

OO-α-D- glucosylglycerate from sucrose and D-glycerate.

Classes IPC  ?

• C12N 9/10 - Transférases (2.)
• C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries

Abrégé

A cell culture medium that sustains the growth of cells obtained from a crustacean in vitro. Indeed, the disclosure describes a cell culture medium comprising a specific salt composition, in part responsible for the correct osmolality and pH, a specific amino acid and vitamin composition, energy sources such as glucose, and crustacean hemolymph. This disclosure further shows that the cell culture medium is capable of keeping cells obtained from shrimp and lobster viable for long periods of time even after passaging the cells into subcultures and inducing the cells to proliferate. The cultured cells are, for example, useful for performing physiological studies on certain genes (by genetic engineering) and for doing research and diagnosis on crustacean pathogens.

Classes IPC  ?

• C12N 5/07 - Cellules animales ou tissus animaux

Abrégé

ApiaceaeApiaceae, the extracts obtained thereof and the use of said extracts as a biopesticide in e.g. agriculture.

Classes IPC  ?

• A01N 65/10 - Apiaceae ou Umbelliferae [famille de la carotte], p. ex. persil, carvi, aneth, livèche, fenouil ou "snakebed" [Cnidium monnieri]
• A01P 3/00 - Fongicides
• A01P 5/00 - Nématicides
• A01P 21/00 - Régulateurs de croissance des végétaux

Abrégé

The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the reaction kinetics.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

The invention relates to the field of CAR-T cell immunotherapy, more specifically the invention relates to production and uses of glyco-engineered CAR-T cells for the improvement of immunotherapy compositions for treatment of cancer, more specifically of solid tumors. The invention specifically relates to human CAR-T cells with a mutated MGAT5 gene, as to provide for surface glycan structures devoid of tetra-antennary N-glycans, which results in a sustained memory when applied in immunotherapy, to cure cancer, reduce (recurrent) tumor growth and tumor burden, as well as to prevent relapse. The invention further relates to methods for manufacturing of those CAR-T cells, wherein addition of low amounts of DMSO during activation and expansion ex vivo skews T cell populations to a more predominant memory phenotype, thereby providing for improved glycol-engineered CAR-T cell compositions for adoptive T cell transfer.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 9/10 - Transférases (2.)
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

The invention relates to a method to deink and/or to delaminate plastic material, preferably to a method to deink and delaminate plastic material in a single step. The method comprises the step of contacting the plastic material with an amine or a composition comprising said amine, wherein the amine comprises a nitrogen atom having at least one hydrocarbon substituent comprising an acyclic or cyclic alkyl group. The total number of carbon atoms of all hydrocarbon substituents of the nitrogen atom is at least (5).

Classes IPC  ?

• C08J 11/28 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance organique par traitement avec des composés organiques contenant de l'azote, du soufre ou du phosphore

Abrégé

The present invention relates to solution electrospun fibers comprising a ingredient in an amorphous form, compositions and their manufacturing process thereof. More specifically, the present invention relates to solution electrospun fibers and a compositions comprising at least one of said fibers, said fiber obtained by solution electrospinning a ingredient with a polymer.

Classes IPC  ?

• C08G 73/02 - Polyamines
• D01D 5/00 - Formation des filaments, fils ou similaires

Abrégé

A method and a circuitry to perform clock and data recovery, CDR is provided. The method includes the steps of obtaining an analogue communication signal characterized by a symbol frequency Fsymbol; and performing an analogue-to-digital conversion of the analogue communication signal according to a sampling rate Fsample targeting Fsymbol*(M/L) thereby obtaining a digital signal. The method includes up-sampling the digital signal by L; filtering the up-sampled digital signal with filter coefficients of a finite impulse response, FIR, filter to perform a fractionally-spaced equalisation; and down-sampling the filtered digital signal by M resulting in a recovered digital signal. Intermediate filter coefficients are obtained for the FIR filter and a phase error is determined based on the recovered digital signal. The intermediate filter coefficients are interpolated based on the phase error to compensate for the phase error, resulting in interpolated filter coefficients; and the filter coefficients of the FIR filter are updated with the interpolated filter coefficients.

Classes IPC  ?

• H04L 7/033 - Commande de vitesse ou de phase au moyen des signaux de code reçus, les signaux ne contenant aucune information de synchronisation particulière en utilisant les transitions du signal reçu pour commander la phase de moyens générateurs du signal de synchronisation, p. ex. en utilisant une boucle verrouillée en phase
• H04L 7/00 - Dispositions pour synchroniser le récepteur avec l'émetteur

Abrégé

Provided herein is a thermometric composition, comprising a plurality of biodegradable periodic mesoporous organosilica, B-PMO, particles, wherein: - each B-PMO particle is loaded with a first dye and a second dye, - the first dye and second dye are both fluorescent, - a fluorescent light emission by the first dye causes a luminescent excitaon of the second dye, - the first dye and/or the second dye exhibit(s) a temperature-dependence fluorescence. Further is provide a method for preparing such thermometric composition, and a method for obtaining temperature data of a cell, a tissue or a subject, using such thermometric composition.

Classes IPC  ?

• C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
• A61B 5/01 - Mesure de la température de parties du corps

Abrégé

The present invention provides a lipid nanoparticle comprising a fentanyl hapten, and a T helper peptide and/or an adjuvant, wherein the fentanyl hapten is conjugated to the outer surface of the lipid nanoparticle, and wherein the T helper peptide and/or the adjuvant is/are encapsulated within the lipid nanoparticle. The invention further provides a pharmaceutical composition comprising the lipid nanoparticle and uses thereof for inducing an immune response against fentanyl and the prevention or treatment of a fentanyl abuse disorder or a fentanyl addiction or a fentanyl overdose in a subject. Further provided herein is a method for preparing the lipid nanoparticle of the invention.

Classes IPC  ?

• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61P 37/04 - Immunostimulants

Abrégé

The invention provides a method for regioselective functionalizing a surface of an electron microscopy grid (10), therefore: a) providing a surface (20) of an electron microscopy grid (101); b) providing a plurality of wall systems (30A, 30B) on the surface of an electron microscopy grid, thereby forming a plurality of temporary reaction chambers (40A, 40B); c) providing a modification solution (50) in each temporary reaction chambers (40A, 40B); d) modifying the parts of the surface (21A, 21B) in the temporary reaction chambers (40A, 40B) with the modification solution(s) (50, 50A, 50B); e) removing the modification solution(s) (50, 50A, 50B) from the temporary reaction chambers (40A, 40B); f) removing the plurality of wall systems (30A, 30B) from the surface (20). The invention provides a method for regioselective functionalizing a surface of an electron microscopy grid (10), therefore: a) providing a surface (20) of an electron microscopy grid (101); b) providing a plurality of wall systems (30A, 30B) on the surface of an electron microscopy grid, thereby forming a plurality of temporary reaction chambers (40A, 40B); c) providing a modification solution (50) in each temporary reaction chambers (40A, 40B); d) modifying the parts of the surface (21A, 21B) in the temporary reaction chambers (40A, 40B) with the modification solution(s) (50, 50A, 50B); e) removing the modification solution(s) (50, 50A, 50B) from the temporary reaction chambers (40A, 40B); f) removing the plurality of wall systems (30A, 30B) from the surface (20). The invention further provides in an electron microscopy grid to be regioselective functionalised and an apparatus for regioselective functionalizing a surface of an electron microscopy grids.

Classes IPC  ?

• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériauMoyens de réglage de diaphragmes ou de lentilles associées au support

Abrégé

Provided is a method or system method for determining a likelihood of a test subject having epilepsy after having suffered a possible epileptic seizure, comprising: - receiving measurement data comprising a measurement parameter set derived from an EEG recording of the test subject in a resting state wherein the measurement parameter set comprises Parameter A of Table 1, - determining from the measurement data the likelihood of the test subject having epilepsy.

Classes IPC  ?

• A61B 5/372 - Analyse des électroencéphalogrammes
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present invention provides co-crystals of the anaplastic lymphoma kinase (ALK) and its ligand ALKAL2 and the related leukocyte tyrosine kinase (LTK) and its ligand ALKAL1. The invention also provides computer-assisted and other methods for selecting molecules able to modulate the interaction between ALK, LTK and their respective ligands.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire

Abrégé

A system for open-path sensing of a property of a fluid in an environment comprises: a sensing light source; a pumping light source for outputting a pumping beam into the environment for inducing a change of light propagation characteristics of the fluid; wherein the system outputs a probing beam and a reference beam into the environment, such that the probing beam has a larger intersection with the pumping beam than the reference beam; wherein a first interferometer detects a phase shift and/or an intensity change of a received probing beam; and wherein a second interferometer detects a phase shift and/or an intensity change of a received reference beam.

Classes IPC  ?

• G01N 21/45 - RéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant des méthodes interférométriquesRéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant les méthodes de Schlieren
• G01F 1/661 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en mesurant la fréquence, le déphasage, le temps de propagation d'ondes électromagnétiques ou d'autres types d'ondes, p. ex. en utilisant des débitmètres à ultrasons en utilisant la lumière
• G01M 3/04 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par détection de la présence du fluide à l'emplacement de la fuite
• G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
• G01N 21/85 - Analyse des fluides ou solides granulés en mouvement

Abrégé

The invention relates to a hafnium (IV) oxide (HfO2) nanoparticle nanocrystal comprising or having a diameter equal or less than (≤) 15 nm, stabilized by a plurality of dispersant molecules attached to its surface. The dispersant molecules comprise of a catechol or gallol surface adsorption moiety and an oligo (ethyleneglycol) moiety. The invention further relates to a composition of such nanoparticles in stable colloidal suspension at physiological pH, and the use of the composition in medical treatment and diagnostic applications, particularly to enhance radiotherapy and as an X ray contrast agent. In yet another aspect, the invention provides a method for manufacturing compositions and nanoparticles according to the invention.

Classes IPC  ?

• A61K 49/04 - Préparations de contraste pour rayons X
• A61K 9/51 - Nanocapsules
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique

Abrégé

The present invention relates to the field of genome-editing, more specific of difficult to transform organisms such as e.g. invertebrates and in particular Arthropoda. The present disclosure provides a combination comprising one or more cationic nanoparticles, one or more endosomal escape reagent(s), and one or more ribonucleoprotein (RNP) complexes wherein said RNP comprises a Cas RNA-guided nuclease associated with a guide RNA (gRNA), and the use thereof in the production of a non-human genetically modified organism. The invention further provides a combination as defined herein for use in CRISPR based methods.

Classes IPC  ?

• A01K 67/61 - Invertébrés génétiquement modifiés, p.ex. transgéniques ou polyploïdes
• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 9/10 - Transférases (2.)
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
• C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12N 9/22 - Ribonucléases

Abrégé

The present application provides methods for determining a respiratory health of a test subject based on mass spectrometry data of a sample of exhaled breath of the test subject. Also provided are methods for assessing the efficacy of a therapeutic treatment of a respiratory disease in a test subject based on mass spectrometry data of one or more samples of exhaled breath of the test subject. Further provided are systems or devices for use in said methods and the use of said systems or devices.

Classes IPC  ?

• G01N 30/72 - Spectromètres de masse

Abrégé

The present invention relates to mutated chitin oligosaccharide synthases and their usage to produce molecules having useful features. More specifically, the present invention discloses the usage of engineered microorganisms expressing a mutated chitin oligosaccharide synthase to produce chitin oligosaccharides having a degree of polymerization of four, five, six or seven.

Classes IPC  ?

• C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
• C12N 9/10 - Transférases (2.)
• C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote

Abrégé

Profiling circuitry for a processor includes state-determining circuitry that is configured to access information stored by the processor for committing inflight instructions in program order, and to use this information to determine a commit state of the processor. The profiling circuitry also has sampling circuitry which is configured, when the processor is in a first commit state, to output sample data to a sample register or a memory that identifies one or more instructions that are next to be committed by the processor, and, when the processor is in a second commit state, to output sample data to the sample register or memory that identifies an instruction that was last committed by the processor.

Classes IPC  ?

• G06F 9/38 - Exécution simultanée d'instructions, p. ex. pipeline ou lecture en mémoire
• G06F 9/30 - Dispositions pour exécuter des instructions machines, p. ex. décodage d'instructions

Abrégé

According to an embodiment a chamber unit (101) is disclosed for a gas-liquid vortex reactor (500) for contacting a first with a second fluid stream comprising a circumferential wall (400, 401) enclosing a cylindrically shaped mixing chamber and a set of tangentially distributed fluid inlet slots (406, 407) axially running from a bottom to a top base to supply the first stream from the outer surface of the wall (400, 401) into the chamber, the wall (400, 401) further comprising a first set of inner axially running between the bottom base towards the top base and comprising a supply inlet (402) at a first end at the bottom base, and a discharge outlet (403) at a second end radially extending from the inner conduit to the inner surface of the wall (400, 401) wherein the inner conduit is configured to supply the second stream from the bottom base into the chamber.

Classes IPC  ?

• B01J 4/00 - Dispositifs d'alimentationDispositifs de commande d'alimentation ou d'évacuation
• B01F 25/10 - Mélange en créant un flux tourbillonnaire, p. ex. par l'introduction tangentielle de composants du flux
• B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
• B01J 19/26 - Réacteurs du type à injecteur, c.-à-d. dans lesquels la distribution des réactifs de départ dans le réacteur est effectuée par introduction ou injection au moyen d'injecteurs

Abrégé

The present invention relates to the field of immunotherapeutical compositions which can be used to treat cancer. More in particular, the present invention discloses dendritic cells loaded with lysates derived from late ferroptotic cancer cells which are useful to treat cancer.

Classes IPC  ?

• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 35/00 - Agents anticancéreux

Abrégé

A method is provided for deriving a surface profile of a free-form master lens for patterning one or two photo-alignment layers of a planar optical component. The method includes obtaining a desired optical function of the planar optical component; and obtaining an actual optical function of the planar optical component, the actual optical function being described as recorded using a free-form test lens with a surface profile configured to provide the desired optical function. The method includes estimating a deviation between the desired optical function and the actual optical function; and correcting the surface profile of the free-form test lens using the estimated deviation, thereby deriving a surface profile for the free-form master lens.

Classes IPC  ?

• G02F 1/1337 - Orientation des molécules des cristaux liquides induite par les caractéristiques de surface, p. ex. par des couches d'alignement
• G01M 11/02 - Test des propriétés optiques

Abrégé

The present invention relates to the field of tissue regeneration, particularly the field of skin lesions such as wounds, more particularly chronic wounds. The invention provides wound healing compositions. Specifically, the invention provides molecules targeting the Slc7a11 transporter such as antibodies, shRNA, siRNA, locked nucleic acids, peptide nucleic acids and morpholinos for use to treat chronic wounds such as for example diabetic wounds.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/46 - Hydrolases (3)
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

There is provided a rotation device comprising a rotor, a stator, a target component, and a sealing device. The rotor is arranged to rotate along a rotation axis relative to the stator. The stator is arranged radial outward of the rotor to form a gap between the rotor and the stator. The sealing device is attached to the rotor to hydrodynamically seal the g against a fluid. The sealing device is adapted to direct the fluid to the target component to exchange heat between the target component and the fluid, and/or to lubricate the target component with the fluid.

Classes IPC  ?

• F01D 25/18 - Systèmes de lubrification
• F01D 11/04 - Prévention ou réduction des pertes internes du fluide énergétique, p. ex. entre étages par obturation non contact, p. ex. du type labyrinthe utilisant un fluide d'obturation, p. ex. de la vapeur
• F16J 15/40 - Joints d'étanchéité entre deux surfaces mobiles l'une par rapport à l'autre par un fluide